Endlyz Therapeutics, Inc. — Form D
Endlyz Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2021-07-29. The offering totals $6.5M, of which $3.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-07-29
- Form: D
- Accession: 0001875514-21-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $6.5M
- Amount sold: $3.3M
- Remaining: $3.3M
- Investors: 6
- Date of first sale: 2021-07-16
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-408116
Issuer
- Name: Endlyz Therapeutics, Inc.
- CIK: 0001875514
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 28 STATE STREET 28 STATE STREET, BOSTON, MA, 02109
- Phone: 44 (0)7436124195
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Jonathan Behr | Director | London, X0 |
| Damian Crowther | Director | Boston, MA |
| John Gustofson | Director | BOSTON, MA |
| Zaven Kaprielian | Director | Boston, MA |
| Zaven Kaprielian | Executive Officer | Boston, MA |
| Joanna Wolak | Executive Officer | BOSTON, MA |
| Laurence Barker | Related Person | BOSTON, MA |
| Donmienne Leung | Related Person | BOSTON, MA |
| Joanna Wolak | Related Person | BOSTON, MA |
| Timothy Edwards | Related Person | BOSTON, MA |
| Justian Craig Fox | Related Person | BOSTON, MA |
Other filings by this issuer (1)
More